Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

Meletios A Dimopoulos; Hartmut Goldschmidt; Rubén Niesvizky; Douglas Joshua; Wee Joo Chng; Albert Oriol; Robert Z. Orlowski; Heinz Ludwig; Thierry Façon; Roman Hájek; Katja Weisel; Vânia Hungria; Leonard Minuk; Shibao Feng; Anita Zahlten‐Kumeli; Amy Kimball; Philippe Moreau

doi:10.1016/s1470-2045(17)30578-8

Related publications

Article2015

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Meletios A Dimopoulos, Philippe Moreau, Antonio Palumbo, Douglas Joshua, Luděk Pour, Roman Hájek, Thierry Façon, Heinz Ludwig, Albert Oriol, Hartmut Goldschmidt, Laura Rosiñol, Jan Štraub, Aleksandr Suvorov, Carla Araujo, Elena Rimashevskaya, Tomáš Pika, Gianluca Gaïdano, Katja Weisel, Vesselina Goranova‐Marinova, Anthony P. Schwarer, Leonard Minuk, Tamás Masszi, Ievgenii Karamanesht, Massimo Offidani, Vânia Hungria, Andrew Spencer, Robert Z. Orlowski, Heidi H. Gillenwater, Nehal Mohamed, Shibao Feng, Wee Joo Chng

Article2017

Carfilzomib–dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study

Hartmut Goldschmidt, Philippe Moreau, Heinz Ludwig, Rubén Niesvizky, Wee Joo Chng, Douglas Joshua, Katja Weisel, Andrew Spencer, Robert Z. Orlowski, Shibao Feng, Karim Iskander, Meletios A Dimopoulos

Article2021

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

Philippe Moreau, Meletios A Dimopoulos, Joseph Mıkhael, Kwee Yong, Marcelo Capra, Thierry Façon, Roman Hájek, Ivan Špıčka, Ross Baker, Kihyun Kım, Gracia Martínez, Chang‐Ki Min, Luděk Pour, Xavier Leleu, Albert Oriol, Youngil Koh, Kenshi Suzuki, Marie‐Laure Risse, Gaëlle Asset, Sandrine Macé, Thomas G. Martin, Philippe Moreau, Meletios A Dimopoulos,

Article2016

Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR

W-J Chng, Hartmut Goldschmidt, Meletios A Dimopoulos, Philippe Moreau, D. Joshua, Antonio Palumbo, Thierry Façon, H. Ludwig, Luděk Pour, Rubén Niesvizky, Albert Oriol, Laura Rosiñol, Aleksandr Suvorov, Gianluca Gaïdano, Tomáš Pika, Katja Weisel, Veselina Goranova‐Marinova, H. H. Gillenwater, Nehal Mohamed, Shibao Feng, Shyam Aggarwal, Roman Hájek

Article2019

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Michèle Cavo, Joan Bladé, Meletios A Dimopoulos, Kenshi Suzuki, Andrzej Jakubowiak, Stefan Knop, Chantal Doyen, Paulo Lúcio, Zsolt Nagy, Luděk Pour, Mark Cook, Sebastian Grosicki, Andre H Crepaldi, Anna Marina Liberati, Philip Campbell, Tatiana Shelekhova, Sung‐Soo Yoon, Genadi Iosava, Tomoaki Fujisaki, Mamta Garg, Maria Krevvata,